Compare Dr. Reddys with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs STRIDES PHARMA SCIENCE - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB STRIDES PHARMA SCIENCE DR. REDDYS LAB/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 40.0 46.9 85.4% View Chart
P/BV x 5.5 2.2 250.3% View Chart
Dividend Yield % 0.5 0.2 218.3%  

Financials

 DR. REDDYS LAB   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-20
STRIDES PHARMA SCIENCE
Mar-18
DR. REDDYS LAB/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs3,3631,147 293.2%   
Low Rs2,352642 366.4%   
Sales per share (Unadj.) Rs1,054.2317.2 332.3%  
Earnings per share (Unadj.) Rs121.97.8 1,554.2%  
Cash flow per share (Unadj.) Rs190.225.1 759.2%  
Dividends per share (Unadj.) Rs25.002.00 1,250.0%  
Dividend yield (eoy) %0.90.2 391.3%  
Book value per share (Unadj.) Rs938.7274.3 342.3%  
Shares outstanding (eoy) m166.1789.50 185.7%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.72.8 96.1%   
Avg P/E ratio x23.4114.0 20.6%  
P/CF ratio (eoy) x15.035.7 42.1%  
Price / Book Value ratio x3.03.3 93.3%  
Dividend payout %20.525.5 80.4%   
Avg Mkt Cap Rs m474,83180,058 593.1%   
No. of employees `00021.72.5 863.6%   
Total wages/salary Rs m33,8024,341 778.8%   
Avg. sales/employee Rs Th8,091.011,325.8 71.4%   
Avg. wages/employee Rs Th1,561.31,731.4 90.2%   
Avg. net profit/employee Rs Th935.8280.1 334.1%   
INCOME DATA
Net Sales Rs m175,17028,394 616.9%  
Other income Rs m6,206941 659.8%   
Total revenues Rs m181,37629,334 618.3%   
Gross profit Rs m24,4213,965 615.9%  
Depreciation Rs m11,3481,540 736.7%   
Interest Rs m9831,962 50.1%   
Profit before tax Rs m18,2961,403 1,303.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m561-168 -333.9%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m-1,40397 -1,441.9%   
Profit after tax Rs m20,260702 2,885.6%  
Gross profit margin %13.914.0 99.8%  
Effective tax rate %-7.76.9 -110.6%   
Net profit margin %11.62.5 467.7%  
BALANCE SHEET DATA
Current assets Rs m125,99124,836 507.3%   
Current liabilities Rs m72,14118,993 379.8%   
Net working cap to sales %30.720.6 149.4%  
Current ratio x1.71.3 133.6%  
Inventory Days Days7371 103.0%  
Debtors Days Days105113 92.4%  
Net fixed assets Rs m83,85434,289 244.6%   
Share capital Rs m831895 92.8%   
"Free" reserves Rs m155,15723,651 656.0%   
Net worth Rs m155,98824,546 635.5%   
Long term debt Rs m1,30415,513 8.4%   
Total assets Rs m232,25365,437 354.9%  
Interest coverage x19.61.7 1,143.6%   
Debt to equity ratio x00.6 1.3%  
Sales to assets ratio x0.80.4 173.8%   
Return on assets %9.14.1 224.6%  
Return on equity %13.02.9 454.1%  
Return on capital %12.66.9 183.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m84,19315,697 536.4%   
Fx outflow Rs m39,616735 5,387.0%   
Net fx Rs m44,57714,962 297.9%   
CASH FLOW
From Operations Rs m29,8411,871 1,595.2%  
From Investments Rs m-4,9235,826 -84.5%  
From Financial Activity Rs m-25,159-10,157 247.7%  
Net Cashflow Rs m-266-2,615 10.2%  

Share Holding

Indian Promoters % 25.5 27.7 92.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 37.8 14.3%  
FIIs % 35.3 8.6 410.5%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 25.9 59.1%  
Shareholders   75,885 56,241 134.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   ALEMBIC PHARMA  DISHMAN PHARMA  TTK HEALTHCARE  ASTRAZENECA PHARMA  DIVIS LABORATORIES  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 244 Points Lower, Nifty Ends Below 14,300; UltraTech Cement & HCL Tech Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended lower.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Warning About Bubbles(Fast Profits Daily)

Apr 16, 2021

Those who don't learn from financial history are doomed to lose their money.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Apr 20, 2021 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS